Monoclonal antibody treatment
SARS-CoV-2 monoclonal antibodies (SMA) have been approved by the FDA for Emergency Use Authorization (EUA) for high-risk outpatients with symptomatic COVID-19 infection. There are 2 monoclonal antibody treatments available.
These medications are administrated via infusion and subcutaneously. The patient could receive one or the other depending on what medication is delivered and available on-site the day of treatment.
EUA fact sheets for healthcare providers
- Casirivimab / imdevimab (Regeneron)
- Adult Monoclonal Antibody for COVID-19 Request Form
- Fact sheet for health care providers emergency use authorization (EUA) of REGEN-COVTM (casirivimab and imdevimab)
EUA fact sheets for patients, parents and caregivers
Please review the emergency use authorization (EUA) with the patient to confirm the patient wants the therapy prior to patient submission:
Please use the Life Sustaining Business List to confirm if patient is classified as an "essential worker."
- Inform patient of a positive test result and verify they are interested in receiving monoclonal antibody therapy prior to referring them for treatment.
- When necessary, patients will be allocated the medications via weighted lottery based on patient eligibility and availability of the medication and infusion resources.
- Eligible patients will be contacted within 2 business days of referral and encouraged to contact their primary provider to notify them of their treatment schedule.
*We accept rapid Covid-19 tests. We do not accept “home testing."
Treatment request forms
Please download and print the relevant document to register the patient and fax to the number provided on the document. Please print and complete the document in its entirety in order to ensure the patient's information is able to be transcribed.